TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01081132
Drug: Extended-release Guanfacine Hydrochloride
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
Study: NCT00268229
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: dose escalation (300 mg/day to 800 mg/day).
Study: NCT01038622
Drug: L-arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day L-arginine treatment
Study: NCT01173497
Drug: INIPARIB + irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21 day cycle
Study: NCT03007446
Drug: Apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib :A starting dose of apatinib was administered 500 mg daily
Study: NCT02071095
Drug: Arm A: Poly-ICLC
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
Study: NCT03007446
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
Study: NCT03007446
Drug: S-1
Normalized name: LIS-1
DrugBank: Tegafur (DB09256)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: S-1:40mg，bid，d1-14，po，in a 21 day cycle.
Study: NCT04190355
Drug: 5.25% Cloraxid gel/ distilled water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.25% Cloraxid gel/ distilled water
Study: NCT00359125
Drug: mifepristone (RU-486)
DrugBank: Mifepristone (DB00834)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: RU-486, 600 mg/day for 1 week.
Study: NCT03856697
Drug: Abivertinib Maleate Capsules
Normalized name: chlorpheniramine maleate Oral Capsule
DrugBank: Abivertinib (DB15327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive the test drug (Abivertinib maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
Study: NCT03856697
Drug: Placebo Gefitinib Tablets
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive the test drug (Placebo Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
Study: NCT03856697
Drug: Gefitinib Tablets
Normalized name: Gefitinib Tablets
DrugBank: Gefitinib (DB00317)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients receive the control drug (Gefitinib Tablets) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 1 tablet. The drugs should be administered with water before or after meals.
Study: NCT03856697
Drug: Placebo Abivertinib Maleate Capsules
DrugBank: Abivertinib (DB15327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients receive the control drug (Placebo Abivertinib Maleate Capsules) since the first day of cycle 1. One cycle is defined as 21 days. The patient shall take the study drugs twice a day. The first dose is 3 capsules, and the second dose is 3 capsules. The drugs should be administered with water before or after meals.
Study: NCT00004002
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00004293
Drug: glucocerebrosidase
Normalized name: PEG glucocerebrosidase
DrugBank: PEG-Glucocerebrosidase (DB17660)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02151617
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Study: NCT00905060
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Maintenance temozolomide treatment is given 2 weeks after administration of the fourth vaccine at an initial dose of 150 mg per square meter (mg/m2) for 5 consecutive days in a 28-day cycle. The dose was increased to 200 mg/m2 for 5 days in subsequent cycles.
Study: NCT04305899
Drug: BMS-986165 Tablet formulation 1
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT04305899
Drug: BMS-986165 Tablet formulation 2
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT02151617
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be decided dose, tablet once daily dosing for 14 days
Study: NCT02151617
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
Study: NCT02151617
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
Study: NCT02151617
Drug: PF-06743649
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, to be decided dose, once daily, 14 days
Study: NCT00871156
Drug: Chloroquine, Tafenoquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine and Tafenoquine
Study: NCT03779451
Drug: vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: vaginal progesterone suppositories (Cyclogest vaginal suppository) in a dose of 400 mg daily starting at 26-28 weeks of gestation till 37 weeks of gestation or delivery
Study: NCT01991197
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.~Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial.
Study: NCT00053209
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00053209
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT03450226
Drug: stellate ganglion block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 or C7. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
Study: NCT04892732
Drug: Budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide dispensing claim is used as the reference group.
Study: NCT04892732
Drug: Budesonide-Formoterol
Normalized name: budesonide-formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide-Formoterol dispensing claim is used as the exposure group.
Study: NCT03163407
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
Study: NCT04030598
Drug: Donidalorsen
Normalized name: Donidalorsen
DrugBank: Donidalorsen (DB18751)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donidalorsen administered SC
Study: NCT00325741
Drug: Hematopoietic Cell Transplantation
Normalized name: human cord blood hematopoietic progenitor cell
DrugBank: Human cord blood hematopoietic progenitor cell (DB11054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
Study: NCT01921010
Drug: Niaspan
Normalized name: Niaspan
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description
Study: NCT03017222
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
Study: NCT03017222
Drug: Ramosetron
Normalized name: ramosetron
DrugBank: Ramosetron (DB09290)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
Study: NCT02439034
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
Study: NCT00001317
Drug: interferon-gamma
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00406679
Drug: Paracetamol (acetaminophen) solution experimental
Normalized name: acetaminophen Oral Solution
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm IV
Study: NCT02563899
Drug: Umeclidinium
Normalized name: Umeclidinium
DrugBank: Umeclidinium (DB09076)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
Study: NCT02549105
Drug: EMLA CREAM 5 mg
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA CREAM APPLICATION FOR WOUND AFTER CS
Study: NCT02549105
Drug: LIDOCAINE 1 %
Normalized name: lidocaine 1 % Topical Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
Study: NCT03781726
Drug: glecaprevir/pibrentasvir treatment
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: combination treatment with glecaprevir and pibrentasvir fixed dose tablet.
Study: NCT02195635
Drug: Telotristat etiprate
Normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg telotristat etiprate
Study: NCT02195635
Drug: Octreotide acetate
Normalized name: Octreotide Acetate
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 µg octreotide acetate three times daily
Study: NCT04241549
Drug: Cusatuzumab
Normalized name: Cusatuzumab
DrugBank: Cusatuzumab (DB15100)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cusatuzumab at a dose 20 milligram per kilogram (mg/kg) once every 2 weeks will be administered intravenously.
Study: NCT04241549
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Azacitidine at a dose 75 milligram per square meters (mg/m\^2) will be administered subcutaneously or intravenously.
Study: NCT00406679
Drug: paracetamol (acetaminophen) solution commercial
Normalized name: acetaminophen Oral Solution
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm IV
Study: NCT02614456
Drug: interferon-gamma and nivolumab
Normalized name: Interferon Gamma
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03172598
Drug: MT-8554 low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsule
Study: NCT03172598
Drug: MT-8554 middle dose
Normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03172598
Drug: MT-8554 high dose
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule
Study: NCT03488420
Drug: Edoxaban Pill
Normalized name: edoxaban Pill
DrugBank: Edoxaban (DB09075)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will be taking edoxaban 30 or 60 mg
Study: NCT00004404
Drug: clotrimazole
Normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004404
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02247466
Drug: Rocuronium and Sugammadex
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00405418
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous injection, once a day in the evening
Study: NCT00405418
Drug: Insulin Detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Subcutaneous injection, twice a day at breakfast and before dinner
Study: NCT00380263
Drug: PACAP38
DrugBank: PACAP38 (DB17073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 pmol/kg/min given one time
Study: NCT01967459
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
Study: NCT01967459
Drug: Cholecalciferol
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
Study: NCT02107846
Drug: PRX-112
Normalized name: PRX-03140
DrugBank: PRX-03140 (DB05596)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02500810
Drug: monosialoganglioside
Normalized name: Monosialoganglioside GM1 antibody
DrugBank: Ganglioside GM1 (DB16948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
Study: NCT04684394
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection
Study: NCT00969709
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
Study: NCT00969709
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
Study: NCT00969709
Drug: Levomilnacipran ER
Normalized name: levomilnacipran Extended Release Oral Capsule
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
Study: NCT00833261
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: cetuximab
Study: NCT00922636
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
Study: NCT00833261
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cisplatin
Study: NCT00833261
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-Paclitaxel
Study: NCT00605215
Drug: Laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laquinimod will be administered per dose and schedule specified in the arm description.
Study: NCT00080457
Drug: sitaxsentan sodium
Normalized name: Sitaxsentan sodium
DrugBank: Sitaxentan (DB06268)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04399070
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The depression patients received propofol and S-ketamine before ECT
Study: NCT04399070
Drug: ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The depression patients received propofol and ketamine before ECT
Study: NCT04399070
Drug: saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The depression patients received propofol and saline before ECT
Study: NCT01991197
Drug: Gliclazide
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind phase (week 0-16):~One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.~Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks.
Study: NCT01991197
Drug: Sitagliptin matched placebo
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
Study: NCT01991197
Drug: Gliclazide matched placebo capsule
Normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-blind phase (week 0-16):~One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks.
Study: NCT03293485
Drug: Imipenem+Cilastatin/Relebactam
DrugBank: Cilastatin (DB01597)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
Study: NCT01451060
Drug: Metaraminol
Normalized name: Metaraminol
DrugBank: Metaraminol (DB00610)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
Study: NCT01451060
Drug: Ephedrine
Normalized name: Ephedrine
DrugBank: Ephedrine (DB01364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
Study: NCT01716897
Drug: E2609
Normalized name: Elenbecestat
DrugBank: Elenbecestat (DB15391)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03127592
Drug: Cyclobenzaprine
Normalized name: Cyclobenzaprine
DrugBank: Cyclobenzaprine (DB00924)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug
Study: NCT00605371
Drug: Lamotrigine tablet
Normalized name: Lamotrigine Tablets
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
Study: NCT00306670
Drug: Rituxan
Normalized name: Rituxan
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
Study: NCT00306670
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: \<30 mg/day
Study: NCT00503139
Drug: Enbrel (etanercept)
Normalized name: etanercept Cartridge [Enbrel]
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Enbrel 10 to 25 mg twice a week subcutaneous injection
Study: NCT00817713
Drug: Praziquantel, Ivermectin, Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard HIV care plus triple anthelminthic treatment~* Praziquantel 2400mg single dose~* Ivermectin 12 mg, single dose~* Albendazole 400mg, 2 doses in 1 day~All drugs given at baseline, after 6 months and after 12 months.
Study: NCT00605371
Drug: Lamotrigine caplet
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.